Therapeutic Advances in Respiratory Disease

SJR Rank #4,845H-index: 59SJR: 1.009Best quartile: Q1Open AccessAPC: US$2,650Listed in DOAJ
Journal website: aims, scope and author guidelines
Publisher

SAGE Publications Ltd

Country

United Kingdom

Type

journal

SJR by Edition

2022202500.30.60.91.2

Subject Categories

  • Pharmacology (medical)Q1
  • Pulmonary and Respiratory MedicineQ1

Areas: Medicine

Most published research topics

Chronic Obstructive Pulmonary Disease (COPD) ResearchAsthma and respiratory diseasesRespiratory Support and MechanismsRespiratory and Cough-Related ResearchInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisCystic Fibrosis Research AdvancesPulmonary Hypertension Research and TreatmentsInhalation and Respiratory Drug DeliveryLung Cancer Diagnosis and TreatmentTracheal and airway disorders

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs060120180240

Documents per Year

202220250306090120

Detailed Information

ISSN

1753-4658, 1753-4666

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

3.19

References per Document

52.76

Coverage

2007-2026

Scope

Therapeutic Advances in Respiratory Disease is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of respiratory disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in respiratory medicine and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of respiratory medicine. The journal publishes original research articles and review articles primarily. Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed.

Metrics from SCImago Journal Rank 2025. View on SCImago